Wanbury Patalganga plant clears Korea FDA inspection with zero observationWanbury Patalganga plant clears Korea FDA inspection with zero observation

Introduction

Leading pharmaceutical manufacturer completed MFDS Korea FDA inspection at its plant with zero observations confirming cGMP compliance and maintaining USFDA approved API production facilities.

Also Read: Paras Defence partners Complus and JV Micronics for advanced chambers

Share price movement of Wanbury

On April 29, 2026, Wanbury Ltd opened at ₹265.00, up 2.71% from its previous close of ₹258.00. The stock reached a high of ₹265.70 (3.00%) and a low of ₹255.55. By 15:31 PM, it traded at ₹259.80, a 0.70% increase, with a market cap of ₹907.73 crore.

Wanbury Korea FDA Inspection Success

Wanbury Limited announced successful completion of MFDS Korea FDA inspection at its Patalganga site. Inspection was conducted over three days from April 7 to April 9, 2026.

The inspection was completed with zero observations, confirming cGMP compliance under international pharmaceutical regulatory standards. MFDS operates under the Pharmaceutical Inspection Co-operation Scheme framework.

The company stated both Patalganga and Tanuku API facilities remain USFDA approved and compliant. Earlier inspections from USFDA and Anvisa Brazil also recorded zero observation status results.

Stock performance of Wanbury for period of 1 week, 6 months, and 1 year

Wanbury Ltd delivered a 1-week return of -3.64%, a 6-month return of -1.14%, and a 1-year return of 6.31%.

Also Read: TCS and ASX go live with CHESS system for clearing and settlement

Shareholding pattern of Wanbury

Particulars	Mar 2026	Dec 2025	Sep 2025
Promoter	43.00%	43.10%	39.60%
FII	0.60%	0.70%	0.80%
DII	0.00%	0.00%	0.00%
Public	56.40%	56%	59.60%

About Wanbury

Wanbury Ltd (NSE: WANBURY) operates in pharmaceuticals, focusing on APIs and formulations, with global API presence across 50 countries and domestic branded formulation business.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs